年間 12 号発行
ISSN 印刷: 1521-9437
ISSN オンライン: 1940-4344
Indexed in
A Phase I/II Study of Ling Zhi Mushroom Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Aphyllophoromycetideae) Extract in Patients with Coronary Heart Disease
要約
The polysaccharides and triterpenes isolated from Ganoderma lucidum have shown hypolipidemic, hypotensive, and antithrombotic effects. This double-blind, randomized, multicentered study was designed to evaluate the clinical effects and safety of extracted G. lucidum polysaccharides (Ganopoly) in patients with confirmed coronary heart disease (CHD). Patients were randomly assigned to receive Ganopoly (n = 88) or placebo (n = 82) for 12 weeks. Effects of therapy on improvement of major symptoms, electrocardiogram (ECG) changes, and serum cholesterol level were investigated. Ten patients were lost to the trial, leaving 80 in each group to be assessed after 12 weeks. The results indicate that patients in both groups were similar with respect to age, gender, serum cholesterol level, and disease duration. Ganopoly treatment gave a significantly higher improved percentage (31.6−54.7%) of the primary symptoms (chest pain, palpitation, angina pectoris, and shortness of breath) in CHD patients compared to the control group (17.2−24.7%). The percentage of abnormal ECG also significantly decreased from 74 to 55% in the treatment group, compared to a decrease of 76 to 74% in the control group. Ganopoly treatment also resulted in a significant decrease of blood pressure, whereas control group did not. The diastolic pressure was decreased by ≥10 mmHg in 22.5% patients receiving Ganopoly. The average blood pressure (systolic/diastolic, 142.5/96.4 mmHg) in this group was reduced to 135.1/92.8 mmHg after 12 weeks of treatment. Serum cholesterol levels decreased significantly after 12 weeks of Ganopoly therapy to the baseline values, whereas cholesterol levels remained unchanged in the control group. Ganopoly is well tolerated and appeared to be active in patients with CHD.
-
Klupp Nerida L, Chang Dennis, Hawke Fiona, Kiat Hosen, Grant Suzanne J, Bensoussan Alan, Klupp Nerida L, Ganoderma lucidum for the treatment of cardiovascular risk factors, in Cochrane Database of Systematic Reviews, 2008. Crossref
-
Klupp Nerida L., Kiat Hosen, Bensoussan Alan, Steiner Genevieve Z., Chang Dennis H., A double-blind, randomised, placebo-controlled trial of Ganoderma lucidum for the treatment of cardiovascular risk factors of metabolic syndrome, Scientific Reports, 6, 1, 2016. Crossref
-
Wasser Solomon P., Medicinal Properties and Clinical Effects of Medicinal Mushrooms, in Edible and Medicinal Mushrooms, 2017. Crossref
-
Zhang Jingsong, Liu Yanfang, Tang Qingjiu, Zhou Shuai, Feng Jie, Chen Hongyu, Polysaccharide of Ganoderma and Its Bioactivities, in Ganoderma and Health, 1181, 2019. Crossref
-
Lee Hyeon A, Cho Jae-Han, Afinanisa Qonita, An Gi-Hong, Han Jae-Gu, Kang Hyo Jeung, Choi Seong Ho, Seong Hyun-A, Ganoderma lucidum Extract Reduces Insulin Resistance by Enhancing AMPK Activation in High-Fat Diet-Induced Obese Mice, Nutrients, 12, 11, 2020. Crossref
-
Krittanawong Chayakrit, Isath Ameesh, Hahn Joshua, Wang Zhen, Fogg Sonya E., Bandyopadhyay Dhrubajyoti, Jneid Hani, Virani Salim S., Tang W.H. Wilson, Mushroom Consumption and Cardiovascular Health: A Systematic Review, The American Journal of Medicine, 134, 5, 2021. Crossref
-
Du Qing, Cao Yuxin, Liu Chang, Lingzhi, An Overview, in The Lingzhi Mushroom Genome, 2021. Crossref
-
Bös Dorothee, Mykotherapie bei Fettstoffwechselstörungen – wertvoller Beitrag von Vitalpilzen, Erfahrungsheilkunde, 70, 05, 2021. Crossref
-
Liu Yadi, Lai Guoxiao, Guo Yinrui, Tang Xiaocui, Shuai Ou, Xie Yizhen, Wu Qingping, Chen Diling, Yuan Xujiang, Protective effect of Ganoderma lucidum spore extract in trimethylamine‐ N ‐oxide‐induced cardiac dysfunction in rats , Journal of Food Science, 86, 2, 2021. Crossref
-
Chan Sze Wa, Tomlinson Brian, Chan Paul, Lam Christopher Wai Kei, The beneficial effects of Ganoderma lucidum on cardiovascular and metabolic disease risk, Pharmaceutical Biology, 59, 1, 2021. Crossref
-
Oke M. A., Afolabi F. J., Oyeleke O. O., Kilani T. A., Adeosun A. R., Olanbiwoninu A. A., Adebayo E. A., Ganoderma lucidum: Unutilized natural medicine and promising future solution to emerging diseases in Africa, Frontiers in Pharmacology, 13, 2022. Crossref
-
Klupp Nerida L, Chang Dennis, Hawke Fiona, Kiat Hosen, Cao Huijuan, Grant Suzanne J, Bensoussan Alan, Ganoderma lucidum mushroom for the treatment of cardiovascular risk factors, Cochrane Database of Systematic Reviews, 2021, 9, 2015. Crossref